complement factor antibodies Search Results


90
R&D Systems goat polyclonal anti complement masp 3
Goat Polyclonal Anti Complement Masp 3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Human+Complement+Factor+MASP3+Catalytic+Domain+Antibody/pmc04883783-118-32-39
Average 90 stars, based on 1 article reviews
goat polyclonal anti complement masp 3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

98
Bio X Cell rat anti mouse cd16 32 clone 2 4g2
Rat Anti Mouse Cd16 32 Clone 2 4g2, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pm41742422-271-18-23
Average 98 stars, based on 1 article reviews
rat anti mouse cd16 32 clone 2 4g2 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

94
R&D Systems human complement factor h antibody
Human Complement Factor H Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Human+Complement+Factor+H+Antibody/pm27399254-41-46-52
Average 94 stars, based on 1 article reviews
human complement factor h antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
R&D Systems anti fhr 2
(a , b) Differences in FH, FHR-1/1 homodimers, FHR-1/2 heterodimers, <t>FHR-2/2</t> homodimers, FHR-3, FHR-4A and FHR-5 homodimers as assessed at the acute stage (samples obtained during the first or second day of hospitalization, n = 106) compared to levels at convalescence ( n = 91). Two children appeared to carry a homozygous CFHR3/CFHR1 deletion, as evidenced by the lack of either protein in their convalescent sample. They were excluded from the analysis for FHR-1/1, FHR-1/2, FHR-2/2 and FHR-3 ( n = 104 and n = 89 for acute stage and convalescence). Acute serum samples comprised 88 samples drawn at day 1 and 18 samples drawn at day 2 of hospitalization, for patients of whom no day 1 sample was available. Levels of FHR-2/2 were calculated based on FHR-1/1 and FHR-1/2 levels. Shaded area indicates 95% range in healthy patients, with dashed line indicating the median. Scatter dot plots depict median and interquartile range (IQR) as red lines. Statistical significance was tested using a Mann-Whitney test. (c) Correlations ( r ) between the relative decreases of FH family proteins (ratios between acute and convalescent levels, by dividing acute levels over convalescent levels) were assessed using Pearson’s measure of association, followed by the Benjamini-Hochberg procedure to control for the false discovery rate (FDR, set to 0.05). Blue shades indicate, from light to dark: p < 0.05; p < 0.01; p < 0.001; and p < 0.0001. ( d ) Examples of correlations in ( c ), showing relative decrease in FH levels versus relative decrease in FHR levels. A:C ratio: acute:convalescent ratio; Conv.: convalescent.
Anti Fhr 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Human+Complement+Factor+H-related+2%2FCFHR2+Antibody/med_rxiv__2021__02__05__21251142-127-20-23
Average 90 stars, based on 1 article reviews
anti fhr 2 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
R&D Systems biotinylated anti mouse fd polyclonal antibody
Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD <t>polyclonal</t> antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.
Biotinylated Anti Mouse Fd Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+D%2FAdipsin+Biotinylated+Antibody/pmc03958157-67-8-16
Average 90 stars, based on 1 article reviews
biotinylated anti mouse fd polyclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

88
Bio-Rad mca2647
Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD <t>polyclonal</t> antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.
Mca2647, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Mouse+anti+Human+Complement+Factor+B+(Ba+Fragment)/pmc05943270-270-10-11
Average 88 stars, based on 1 article reviews
mca2647 - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

94
Proteintech cfb
Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD <t>polyclonal</t> antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.
Cfb, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Complement+factor+B+Antibody/pm40820810-262-25-26
Average 94 stars, based on 1 article reviews
cfb - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Proteintech fhr 3 gst fusion protein
Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD <t>polyclonal</t> antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.
Fhr 3 Gst Fusion Protein, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/CFHR3+Antibody/pm28533443-64-12-18
Average 94 stars, based on 1 article reviews
fhr 3 gst fusion protein - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
R&D Systems sheep anti fh
Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD <t>polyclonal</t> antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.
Sheep Anti Fh, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+H+Antibody/pm35277417-76-49-54
Average 92 stars, based on 1 article reviews
sheep anti fh - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
R&D Systems mab3845
a Overview of the VEBIOS ER discovery cohort. 756 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (median fluorescent intensity) signal were calculated between VTE cases ( n = 48) and controls ( n = 48) in ( b ) citrate or ( c ) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls ( n = 48) and cases ( n = 48) in ( d ) citrate plasma and ( e ) EDTA plasma. f Immunocapture-mass spectrometry identification of protein targets of HPA059937 ( n = 3 of independent biological replicates). g Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with HPA059937 (raised against SULF1), anti-CFHR5 HPA073894 or anti-CFHR5 HPA072446 as capture antibodies. Monoclonal anti-CFHR5 <t>(MAB3845)</t> was applied as detection antibody in the three combinations. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine levels (MFI) in controls ( n = 48) vs . cases ( n = 48) and the correlation between the signal and those generated by the original single binder assay using HPA059937 [all p < 1E-04]. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard and MAB3845 as detection antibody, was used for absolute quantification of CFHR5 in samples from: ( h ) VEBIOS ER and ( i ) VEBIOS Coagulation (controls = 135, cases = 142). CFHR5 concentration was measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase [ h and i , left]) or used to determine the correlation with C-reactive protein (CRP), or D-dimer concentration [ h and i , right panels]. All data in dot plots (1 d – i ) are represented as median value with 95% CI (confidence interval). Case and control groups was compared using a linear model adjusting for age and sex in d , e , g , h and i .***** p < 0.00001, **** p < 0.0001, *** p < 0.001, ** p < 0.01. Two-sided Spearman´s correlation analysis for h and i . For summary statistics see Supplementary data <xref ref-type=1 [Tab_2, Panel A] . Source data are provided as a Source Data file ( b – i ). " width="250" height="auto" />
Mab3845, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Human+Complement+Factor+H-related+5%2F+CFHR5+Antibody/pmc10247781-425-18-19
Average 93 stars, based on 1 article reviews
mab3845 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Proteintech cfp polyclonal antibody
a Overview of the VEBIOS ER discovery cohort. 756 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (median fluorescent intensity) signal were calculated between VTE cases ( n = 48) and controls ( n = 48) in ( b ) citrate or ( c ) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls ( n = 48) and cases ( n = 48) in ( d ) citrate plasma and ( e ) EDTA plasma. f Immunocapture-mass spectrometry identification of protein targets of HPA059937 ( n = 3 of independent biological replicates). g Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with HPA059937 (raised against SULF1), anti-CFHR5 HPA073894 or anti-CFHR5 HPA072446 as capture antibodies. Monoclonal anti-CFHR5 <t>(MAB3845)</t> was applied as detection antibody in the three combinations. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine levels (MFI) in controls ( n = 48) vs . cases ( n = 48) and the correlation between the signal and those generated by the original single binder assay using HPA059937 [all p < 1E-04]. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard and MAB3845 as detection antibody, was used for absolute quantification of CFHR5 in samples from: ( h ) VEBIOS ER and ( i ) VEBIOS Coagulation (controls = 135, cases = 142). CFHR5 concentration was measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase [ h and i , left]) or used to determine the correlation with C-reactive protein (CRP), or D-dimer concentration [ h and i , right panels]. All data in dot plots (1 d – i ) are represented as median value with 95% CI (confidence interval). Case and control groups was compared using a linear model adjusting for age and sex in d , e , g , h and i .***** p < 0.00001, **** p < 0.0001, *** p < 0.001, ** p < 0.01. Two-sided Spearman´s correlation analysis for h and i . For summary statistics see Supplementary data <xref ref-type=1 [Tab_2, Panel A] . Source data are provided as a Source Data file ( b – i ). " width="250" height="auto" />
Cfp Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/CFP+Antibody/pm39792656-455-43-50
Average 93 stars, based on 1 article reviews
cfp polyclonal antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
R&D Systems masp3 ab mab1724
a Overview of the VEBIOS ER discovery cohort. 756 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (median fluorescent intensity) signal were calculated between VTE cases ( n = 48) and controls ( n = 48) in ( b ) citrate or ( c ) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls ( n = 48) and cases ( n = 48) in ( d ) citrate plasma and ( e ) EDTA plasma. f Immunocapture-mass spectrometry identification of protein targets of HPA059937 ( n = 3 of independent biological replicates). g Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with HPA059937 (raised against SULF1), anti-CFHR5 HPA073894 or anti-CFHR5 HPA072446 as capture antibodies. Monoclonal anti-CFHR5 <t>(MAB3845)</t> was applied as detection antibody in the three combinations. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine levels (MFI) in controls ( n = 48) vs . cases ( n = 48) and the correlation between the signal and those generated by the original single binder assay using HPA059937 [all p < 1E-04]. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard and MAB3845 as detection antibody, was used for absolute quantification of CFHR5 in samples from: ( h ) VEBIOS ER and ( i ) VEBIOS Coagulation (controls = 135, cases = 142). CFHR5 concentration was measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase [ h and i , left]) or used to determine the correlation with C-reactive protein (CRP), or D-dimer concentration [ h and i , right panels]. All data in dot plots (1 d – i ) are represented as median value with 95% CI (confidence interval). Case and control groups was compared using a linear model adjusting for age and sex in d , e , g , h and i .***** p < 0.00001, **** p < 0.0001, *** p < 0.001, ** p < 0.01. Two-sided Spearman´s correlation analysis for h and i . For summary statistics see Supplementary data <xref ref-type=1 [Tab_2, Panel A] . Source data are provided as a Source Data file ( b – i ). " width="250" height="auto" />
Masp3 Ab Mab1724, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+antibodies/Human+Complement+Factor+MASP3+Catalytic+Domain+Antibody/pm33858964-67-4-9
Average 90 stars, based on 1 article reviews
masp3 ab mab1724 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


(a , b) Differences in FH, FHR-1/1 homodimers, FHR-1/2 heterodimers, FHR-2/2 homodimers, FHR-3, FHR-4A and FHR-5 homodimers as assessed at the acute stage (samples obtained during the first or second day of hospitalization, n = 106) compared to levels at convalescence ( n = 91). Two children appeared to carry a homozygous CFHR3/CFHR1 deletion, as evidenced by the lack of either protein in their convalescent sample. They were excluded from the analysis for FHR-1/1, FHR-1/2, FHR-2/2 and FHR-3 ( n = 104 and n = 89 for acute stage and convalescence). Acute serum samples comprised 88 samples drawn at day 1 and 18 samples drawn at day 2 of hospitalization, for patients of whom no day 1 sample was available. Levels of FHR-2/2 were calculated based on FHR-1/1 and FHR-1/2 levels. Shaded area indicates 95% range in healthy patients, with dashed line indicating the median. Scatter dot plots depict median and interquartile range (IQR) as red lines. Statistical significance was tested using a Mann-Whitney test. (c) Correlations ( r ) between the relative decreases of FH family proteins (ratios between acute and convalescent levels, by dividing acute levels over convalescent levels) were assessed using Pearson’s measure of association, followed by the Benjamini-Hochberg procedure to control for the false discovery rate (FDR, set to 0.05). Blue shades indicate, from light to dark: p < 0.05; p < 0.01; p < 0.001; and p < 0.0001. ( d ) Examples of correlations in ( c ), showing relative decrease in FH levels versus relative decrease in FHR levels. A:C ratio: acute:convalescent ratio; Conv.: convalescent.

Journal: medRxiv

Article Title: Loss of Factor H family proteins associates with meningococcal disease severity

doi: 10.1101/2021.02.05.21251142

Figure Lengend Snippet: (a , b) Differences in FH, FHR-1/1 homodimers, FHR-1/2 heterodimers, FHR-2/2 homodimers, FHR-3, FHR-4A and FHR-5 homodimers as assessed at the acute stage (samples obtained during the first or second day of hospitalization, n = 106) compared to levels at convalescence ( n = 91). Two children appeared to carry a homozygous CFHR3/CFHR1 deletion, as evidenced by the lack of either protein in their convalescent sample. They were excluded from the analysis for FHR-1/1, FHR-1/2, FHR-2/2 and FHR-3 ( n = 104 and n = 89 for acute stage and convalescence). Acute serum samples comprised 88 samples drawn at day 1 and 18 samples drawn at day 2 of hospitalization, for patients of whom no day 1 sample was available. Levels of FHR-2/2 were calculated based on FHR-1/1 and FHR-1/2 levels. Shaded area indicates 95% range in healthy patients, with dashed line indicating the median. Scatter dot plots depict median and interquartile range (IQR) as red lines. Statistical significance was tested using a Mann-Whitney test. (c) Correlations ( r ) between the relative decreases of FH family proteins (ratios between acute and convalescent levels, by dividing acute levels over convalescent levels) were assessed using Pearson’s measure of association, followed by the Benjamini-Hochberg procedure to control for the false discovery rate (FDR, set to 0.05). Blue shades indicate, from light to dark: p < 0.05; p < 0.01; p < 0.001; and p < 0.0001. ( d ) Examples of correlations in ( c ), showing relative decrease in FH levels versus relative decrease in FHR levels. A:C ratio: acute:convalescent ratio; Conv.: convalescent.

Article Snippet: FHR-1/1 homodimers and FHR-1/2 heterodimers were captured using clone anti-FH.02 (Sanquin Research), and detected with biotinylated anti-FH.02 (Sanquin Research) or anti-FHR-2 (clone MAB5484, R&D Systems, Minneapolis, MN, USA), respectively.

Techniques: MANN-WHITNEY

Serum levels of FH, FHR-1/1, FHR-1/2, FHR-2/2, FHR-3, FHR-4A and FHR-5 at the acute stage of patients who did ( n = 15) or did not ( n = 90) receive renal support. Both surviving and non-surviving patients are included here. Statistical significance was tested using a Mann-Whitney test. Lines depict median and IQR. ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05; ns = not significant.

Journal: medRxiv

Article Title: Loss of Factor H family proteins associates with meningococcal disease severity

doi: 10.1101/2021.02.05.21251142

Figure Lengend Snippet: Serum levels of FH, FHR-1/1, FHR-1/2, FHR-2/2, FHR-3, FHR-4A and FHR-5 at the acute stage of patients who did ( n = 15) or did not ( n = 90) receive renal support. Both surviving and non-surviving patients are included here. Statistical significance was tested using a Mann-Whitney test. Lines depict median and IQR. ****: p < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05; ns = not significant.

Article Snippet: FHR-1/1 homodimers and FHR-1/2 heterodimers were captured using clone anti-FH.02 (Sanquin Research), and detected with biotinylated anti-FH.02 (Sanquin Research) or anti-FHR-2 (clone MAB5484, R&D Systems, Minneapolis, MN, USA), respectively.

Techniques: MANN-WHITNEY

Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD polyclonal antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.

Journal: Clinical and Experimental Immunology

Article Title: C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo

doi: 10.1111/cei.12244

Figure Lengend Snippet: Western blot analysis of factor D (FD) and factor B (FB) in Cfh –/– , Cfh –/– .mannan-binding lectin-associated serine proteases ( MASP )-1/3 –/– and MASP-1/3 –/– mice. (a) FD in mouse plasma was immunoprecipitated with goat anti-FD polyclonal antibody, incubated with N-glycosidase and analysed by immunoblotting. Evidence of pro-FD was seen in MASP-1/3 –/– (lanes 2 and 3) and Cfh –/– . MASP-1/3 –/– (lanes 6 and 7) mice. In wild-type and Cfh –/– animals FD was evident in addition to an unidentified higher molecular weight band. The Western blot was not designed to allow FD quantification. (b) Plasma from wild-type (lanes 1 and 3) and MASP-1/3 –/– mice (lanes 2 and 4) was subjected to immunoprecipitation with goat anti-FD (lanes 1 and 2) or goat anti-C3 (lanes 3 and 4) polyclonal antibodies. The immunoprecipitated proteins were incubated with N-glycosidase and analysed for FD by immunoblotting. FD-related bands were observed after immunoprecipitation with goat anti-FD antibody (lanes 1 and 2) and no cross-reactivity with mouse or goat immunoglobulins was evident (lanes 3 and 4). IP: immunoprecipitation. (c) FB was analysed by Western blotting under reduced conditions. Intact FB and Ba fragments were detected using anti-human FB polyclonal serum that cross-reacts with mouse FB. The Bb fragment could not be assessed accurately, as a background band with similar molecular weight (∼55 kDa) was observed in the Cfb –/– . Data are representative of two independent experiments.

Article Snippet: FD was detected using Western blot with a biotinylated anti-mouse FD polyclonal antibody (product no. BAF5430; R&D Systems) and streptavidin–HRP (product no. P0397; Dako, Glostrup, Denmark).

Techniques: Western Blot, Binding Assay, Clinical Proteomics, Immunoprecipitation, Incubation, Molecular Weight

a Overview of the VEBIOS ER discovery cohort. 756 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (median fluorescent intensity) signal were calculated between VTE cases ( n = 48) and controls ( n = 48) in ( b ) citrate or ( c ) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls ( n = 48) and cases ( n = 48) in ( d ) citrate plasma and ( e ) EDTA plasma. f Immunocapture-mass spectrometry identification of protein targets of HPA059937 ( n = 3 of independent biological replicates). g Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with HPA059937 (raised against SULF1), anti-CFHR5 HPA073894 or anti-CFHR5 HPA072446 as capture antibodies. Monoclonal anti-CFHR5 (MAB3845) was applied as detection antibody in the three combinations. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine levels (MFI) in controls ( n = 48) vs . cases ( n = 48) and the correlation between the signal and those generated by the original single binder assay using HPA059937 [all p < 1E-04]. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard and MAB3845 as detection antibody, was used for absolute quantification of CFHR5 in samples from: ( h ) VEBIOS ER and ( i ) VEBIOS Coagulation (controls = 135, cases = 142). CFHR5 concentration was measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase [ h and i , left]) or used to determine the correlation with C-reactive protein (CRP), or D-dimer concentration [ h and i , right panels]. All data in dot plots (1 d – i ) are represented as median value with 95% CI (confidence interval). Case and control groups was compared using a linear model adjusting for age and sex in d , e , g , h and i .***** p < 0.00001, **** p < 0.0001, *** p < 0.001, ** p < 0.01. Two-sided Spearman´s correlation analysis for h and i . For summary statistics see Supplementary data <xref ref-type=1 [Tab_2, Panel A] . Source data are provided as a Source Data file ( b – i ). " width="100%" height="100%">

Journal: Nature Communications

Article Title: Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism

doi: 10.1038/s41467-023-38383-y

Figure Lengend Snippet: a Overview of the VEBIOS ER discovery cohort. 756 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (median fluorescent intensity) signal were calculated between VTE cases ( n = 48) and controls ( n = 48) in ( b ) citrate or ( c ) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls ( n = 48) and cases ( n = 48) in ( d ) citrate plasma and ( e ) EDTA plasma. f Immunocapture-mass spectrometry identification of protein targets of HPA059937 ( n = 3 of independent biological replicates). g Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with HPA059937 (raised against SULF1), anti-CFHR5 HPA073894 or anti-CFHR5 HPA072446 as capture antibodies. Monoclonal anti-CFHR5 (MAB3845) was applied as detection antibody in the three combinations. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine levels (MFI) in controls ( n = 48) vs . cases ( n = 48) and the correlation between the signal and those generated by the original single binder assay using HPA059937 [all p < 1E-04]. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard and MAB3845 as detection antibody, was used for absolute quantification of CFHR5 in samples from: ( h ) VEBIOS ER and ( i ) VEBIOS Coagulation (controls = 135, cases = 142). CFHR5 concentration was measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase [ h and i , left]) or used to determine the correlation with C-reactive protein (CRP), or D-dimer concentration [ h and i , right panels]. All data in dot plots (1 d – i ) are represented as median value with 95% CI (confidence interval). Case and control groups was compared using a linear model adjusting for age and sex in d , e , g , h and i .***** p < 0.00001, **** p < 0.0001, *** p < 0.001, ** p < 0.01. Two-sided Spearman´s correlation analysis for h and i . For summary statistics see Supplementary data 1 [Tab_2, Panel A] . Source data are provided as a Source Data file ( b – i ).

Article Snippet: IC-MS was performed in triplicate of pooled plasma, as previously described using the HPA059937 antibody (Atlas Antibodies) or MAB3845 (R&D systems, clone:390513) and rabbit or mouse immunoglobulin G (rIgG, AB-105-C [R&D] and PMP01X [Biorad], respectively) as respective negative controls.

Techniques: Clinical Proteomics, Generated, Mass Spectrometry, Recombinant, Quantitative Proteomics, Coagulation, Concentration Assay, Standard Deviation, Control